Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00478179
Status:
COMPLETED
Last Update Posted:
2009-09-11
First Post:
2007-05-22
Brief Title:
Study of a Bupivacaine Patch Eladur to Treat Post- Herpetic Neuralgia
Sponsor:
Durect
Organization:
Durect
Study Overview
Official Title:
A Randomized Double-Blind Placebo Controlled Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients With Post-Herpetic Neuralgia
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neuropathic pain is caused by a virus commonly associated with chicken pox This virus may become dormant in the nervous system and later reactivate causing herpes zoster also known as shingles Post-herpetic neuralgia PHN is a persistent pain in the area of healed skin lesions This study will test the safety and efficacy of treating PHN patients with the analgesic patch Bupivacaine TTS Eladur
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None